Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021

The Title of his Talk Will be “From Biology to Treatment – Anti-TNF in Dupuytren’s Disease”, to be Presented During the Opening Session, “The Cutting Edge: Advancing the Science of Hand Surgery”

PALO ALTO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that Jagdeep Nanchahal, Professor of Hand, Plastic and Reconstructive Surgery at the University of Oxford, and Chairman of the Company’s Clinical Advisory Board, is scheduled to present a key note talk at the British Society for Surgery of the Hand (BSSH) meeting on Thursday September 9, 2021 at 9:00 AM British Standard Time (4:00 AM Eastern Standard Time).

Professor Nanchahal will present an overview of his extensive breakthrough scientific research in defining the molecular pathways of the fibrotic process in Dupuytren’s disease, which causes the fingers to curl irreversibly into the palm, and potential therapeutic approaches.

Dr. James Woody, 180 Life Sciences’ Chief Executive Officer, stated “We are especially pleased Professor Nanchahal can present his scientific work to clinical colleagues who have extensive experience of treating patients with late-stage disease.”

Professor Jagdeep Nanchahal commented, “By systematically analyzing tissues normally discarded at the time of surgery, we were able to identify a potential therapeutic target and progress through to testing in patients with early stage Dupuytren’s disease.”

About 180 Life Sciences Corp.

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary, most advanced platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor) which is in the clinic.

Forward-Looking Statements

This press release includes “forward-looking statements”, including information about management’s view of the Company’s future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the “Act”). Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation: the risk that initial drug results will not be able to be replicated in clinical trials or that such drugs selected for clinical development will not be successful; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; statements relating to expectations regarding the capitalization, resources, and funding of the Company; expectations with respect to future performance, growth and anticipated acquisitions; the continued listing of the Company’s securities on The NASDAQ Stock Market; the ability of the Company to execute its plans to develop and market new drug products and the timing and costs of these development programs; estimates of the size of the markets for its potential drug products; potential litigation involving the Company; the validity or enforceability of the intellectual property of the Company; global economic conditions; geopolitical events and regulatory changes; the expectations, development plans and anticipated timelines for the Company's drug candidates, pipeline and programs, including collaborations with third parties; access to additional financing, and the potential lack of such financing; and the Company’s ability to raise funding in the future and the terms of such funding. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Annual Reports on Form 10-Ks, Quarterly Reports on Form 10-Qs and Current Reports on Form 8-Ks. These reports and filings are available at All subsequent written and oral forward-looking statements concerning the Company or other matters and attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as otherwise provided by law.


Jason Assad
Director of IR
180 Life Sciences Corp
(678) 570-6791

Media Relations:

Russo Partners
David Schull
(212) 845-4271

Source: 180 Life Sciences Corp.